Novartis Canada applauds Canada’s Drug Agency (CDA-AMC) for its positive draft recommendation to reimburse Kisqali® ...
BACKGROUND: The disruption of the blood–brain barrier (BBB) is a central pathogenic event in many central nervous system disorders. However, the mechanisms regulating BBB function remain incompletely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results